Nervomatrix investigated the effectiveness of the SOLEVE® Auto-Targeted Neurostimulation system in a 19-patient study at the Physical Therapy unit at the Bnai Zion Medical Center in Haifa, Israel.
Protocol - Of the 19 patients, five were females (79%) and four were men (21%) with a mean age of 52.1±10.8 years. All were diagnosed with non-specific chronic low back pain. The protocol consisted of six treatment sessions, 2-4 days apart. Each session included a <1 minute automatic impedance screening, followed by a 20-minute treatment of the lowest impedance points according to the company’s proprietary algorithms.
Primary Outcome - The primary outcome measure consisted of changes in pain intensity as measured on a 100 mm pain visual analogue scale (VAS) obtained at enrollment, before and 2 hours after each treatment.
Result - The mean ±SD baseline VAS score for all participants was 61±14. During treatment, VAS scores decreased significantly compared with baseline scores by 39±17 mm (p< 0.001). Notably, VAS scores of all the patients, except for one, decreased by more than 20 mm after the fourth treatment, therefore showing marked improvement in 95% of enrolled patients.
95% Showed a 20-Point Reduction in VAS Score After Forth Session
Clinical Track Record